consolidation chemotherapy
Phase 3Small molecule
consolidation chemotherapy is one of 18 small molecule programs targeting Rectal Neoplasms. It is currently in Phase 3.
2
Indications
9
Total Trials
3
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
13 competitors in Total Neoadjuvant Therapy
#DrugCompanyPhaseTrials
1Eloxatin
TevaPhase 2
Beyfortus
BeiGenePhase 2
Avastin
RochePhase 2
Serplulimab
Shanghai Henlius BiotechPhase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 2
Mfolfox6
RochePhase 2
PD-1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 2
Pucotenlimab
SSun Yat-sen University
Phase 2
GLP-1 Receptor Agonist
Boehringer IngelheimPhase 2
Envafolimab
TTracon Pharmaceuticals Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Locally-advanced Rectal Cancer2 trials
Total Neoadjuvant Therapy2 trials
Total Neoadjuvant Therapy in Rectal Cancer Treatment
Unknown status·SState Scientific Centre of Coloproctology, Russian Federation·Phase 4·NCT04747951·280 enrolled
Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.
Recruiting·—·Phase 2/3·NCT06758830·400 enrolled
Chemoradiotherapy1 trial
A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk
Unknown status·—·Phase 2·NCT04664504·150 enrolled
2 more indications
Rectal Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for consolidation chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SShenzhen People's Hospital